Effect of ursodeoxycholic acid for reducing the deficit of vitamin D status and bone mineral density at gallstones

AIM To study the effect of ursodeoxycholic acid on vitamin D levels and bone mineral density (BMD) in patients with gallstone disease (GSD). MATERIALS AND METHODS BMD assessed by dual-energy X-ray densitometry in 53 patients with gallstone disease, of whom 21 patients received litolitic therapy at a daily dose of 10 mg/kg for 1,5-2 years. The control group consisted of 15 persons matched by sex and age. RESULTS Patients with gallstone disease treated with UDCA (ursosan), vitamin D deficiency was found in 5%, and in patient that didn't receive litolitic therapy--in 69% of cases. CONCLUSION Ursotherapy in patients with gallstone disease reduces vitamin D deficiency and is an effective measure to prevent osteopenia.